Trial Profile
Serum levels of vascular endothelial growth factor (VEGF) before and after intravitreal injection of conbercept or ranibizumab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2017
Price :
$35
*
At a glance
- Drugs Conbercept (Primary) ; Ranibizumab (Primary)
- Indications Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
- Focus Pharmacodynamics
- 28 Oct 2017 New trial record